HANGZHOU HOLYPHARM BIOTECH CO.,LTD

HANGZHOU HOLYPHARM BIOTECH CO.,LTD
Country:  China (Mainland)
Business Type:  Other
    x
  • Mr.Leonard Chang
Mr.Leonard
Tel: 86 571 86853097
Fax:  86 571 87357695
City:  Hangzhou
Street:  Room D808, Block 4 NO.176, Zixia Rd
MaxCard:
Home > Products > 

ROSUVASTATIN

ROSUVASTATIN CAS NO.147098-20-2

  • FOB Price: USD: 1.00-1.00 /Metric Ton Get Latest Price
  • Min.Order: 10 Gram
  • Payment Terms: L/C,T/T
  • Available Specifications:

    1(1-2)Metric Ton1(1-2)Metric Ton

  • Product Details

Keywords

  • rosuvastatin calcium
  • atorvastatin calcium
  • 147098-20-2

Quick Details

  • ProName: ROSUVASTATIN
  • CasNo: 147098-20-2
  • Molecular Formula: C44H54CaF2N6O12S2
  • Appearance: powder
  • Application: cardiovascular disease
  • DeliveryTime: promptly
  • PackAge: 5-25 kg per drum
  • Port: shanghai
  • ProductionCapacity: 1 Kilogram/Day
  • Purity: 1
  • Storage: dry price
  • Transportation: cif air
  • LimitNum: 10 Gram
  • Related Substances: 1
  • Residue on Ignition: 1
  • Heavy Metal: 1
  • Valid Period: 1

Superiority

EDMF, EUGMP, high quality,

Details

EDMF, EUGMP, high quality,

Rosuvastatin (marketed by AstraZeneca as Crestor, Abbott Laboratories as R2) is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fifth-highest selling drug in the United States, accounting for approx. $2.6 billion in sales in 2013 .

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia).[11] In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.[12]

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.[13]

The results of the JUPITER trial (2008) suggested rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia, but with elevated levels of highly sensitive C-reactive protein. This could strongly impact medical practice by placing many patients on statin prophylaxis who otherwise would have been untreated.[14][15] As a result of this clinical trial, the FDA approved rosuvastatin for the primary prevention of cardiovascular events.[12]

The AURORA trial randomized 2776 patients undergoing hemodialysis due to kidney damage to receive either rosuvastatin or placebo. The randomized, double-blind study (2005 to 2009) found no difference in the two groups in the primary end-point, a combination of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The study found no difference in all-cause mortality among this population at a mean follow-up of 3.8 years

Other products of this supplier